CD47 and neoplasm: Altogether, we demonstrate that IR700@Nb289‐OMVs plus NIR can synergistically enhance the antitumour efficacy of PD‐1 and CD47 blockade therapies; it seems that, combined with the CD47 blockade, IR700@Nb289‐OMVs plus NIR can exert better antitumour activity and partially result in tumour eradication, possibly inducing durable antitumour immune memory.